Nautilus Biotechnology, Inc.
9.10%
11,634,211
1808805
Jun 29, 2026
Aug 14, 2026, 05:20 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | Investment Adviser | 9.10% | 11,634,211 | 0 | 11,634,211 |
| Joseph Edelman | Individual | 9.10% | 11,634,211 | 0 | 11,634,211 |
| Perceptive Life Sciences Master Fund, Ltd. | CO | 9.10% | 11,468,351 | 0 | 11,468,351 |
| C2 Life Sciences LLC | CO | 0.10% | 165,860 | 0 | 165,860 |
Disclosure Items (2)
Common Stock, par value $0.0001 per share
Nautilus Biotechnology, Inc.
2701 Eastlake Avenue East, Seattle, WA, 98102
Item 5(a) of the Schedule 13D is hereby amended and restated as follows: The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentages set forth in row 13 are based on 127,255,223 shares of Common Stock outstanding as of July 24, 2026, as disclosed by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on July 28, 2026.
The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference. Neither Perceptive Advisors LLC ( "Perceptive Advisors") nor Joseph Edelman ("Mr. Edelman") directly holds any Common Stock. Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund") directly holds 11,468,351 shares of Common Stock, and C2 Life Sciences LLC ("C2") directly holds 165,860 shares of Common Stock. Perceptive Advisors serves as the investment manager to the Master Fund and C2. Mr. Edelman is the managing member of Perceptive Advisors.